User Experiences 

DSS Imagetech Pvt. Ltd. would like to acknowledge all the wonderful authors who have contributed to the scientific community by sharing their research. 

We are proud to be a small part of your research by the mention of our products or technology in them. We hope and wish that you continue to scale new heights in your research and bring more such accolades to yourself, your institute and the country.

STANDARDIZE AND SECURE THE FREEZING OF TISSUES WITH FlashFREEZE

Anatomo-CytoPathology Laboratory will be located just above the operating rooms. The use of liquid nitrogen has been compromised for logistical reasons, as it would have required a dedicated elevator to transport liquid nitrogen to our facility and could not be stored near care facilities and operating rooms. Indeed, liquid nitrogen presents several dangers: anoxia in case of excessive evaporation; it can take the place of ambient oxygen; there is also a risk of cryogenic burn when handled; fi nally a risk of explosion if it is trapped inside a container

Read More

NEW TECHNOLOGY MINIMIZES EXPOSURE TO FORMALIN

When Prof. Dr. Hans Michael Kvasnicka and Ralf Lieberz began their work to minimize sta exposure to formalin, buckets for biospecimens were cleaned from formalin after use. This was done to save money on buckets. But on closer analysis, it turned out that it was not economically viable. Sta costs for cleaning were higher than using new buckets; sta were also constantly exposed to formalin. Moreover, there was a risk of contamination between biospecimens, which could a ect the result of the diagnosis and eventually patient safety

Read More

Rapid Identification of Key Copy Number Alterations in B- and T-cell Acute Lymphoblastic Leukaemia by Digital Multiplex Ligation-Dependent Probe Amplification*

• Paper: Rapid Identification of Key Copy Number Alterations in B- and T-cell Acute Lymphoblastic Leukaemia by Digital Multiplex Ligation-Dependent Probe Amplification*
• Journal: Frontiers in Oncology, section Hematologic Malignancies
• Article type: Original Research
• Authors: Deepshi Thakral¹, Gurvinder Kaur¹, Ritu Gupta¹, Anne Benard², Suvi Savola², Indresh Kumar Singh¹, Rajni Anand¹, Lata Rani¹, Pramod Verma¹, Sangeeta Vashishtha¹, Lalit Kumar³,Atul Sharma³, Sameer Bakhshi³, Rachna Seth⁴, Vivek Singh¹

*Research was done using SALSA® digitalMLPA probemix D007 ALL, a digitalMLPA probemix not currently on the market.

¹Laboratory Oncology Unit, Dr. BRA IRCH, All India Institute of Medical Sciences, New Delhi, India

²MRC Holland, Department of Tumour Diagnostics, Amsterdam, Netherlands

³Department of Medical Oncology, Dr. BRA IRCH, All India Institute of Medical Sciences, New Delhi, India

⁴Department of Pediatrics, All India Institute of Medical Sciences, New Delhi, India

An excerpt from the paper:

Recently, a next-generation sequencing-based Multiplex Ligation-dependent Probe Amplification (MLPA) variant, digitalMLPA (dMLPA) was developed to detect sub-microscopic CNAs, which might be missed by existing conventional, and high-resolution technologies (19). The available molecular diagnostic tools for detection of these key genetic abnormalities to distinguish various subtypes of ALL include conventional karyotyping, FISH, aCGH, SNP arrays, and conventional MLPA which are tedious and time-consuming. dMLPA allows multiplexing of several targets for accurate copy number detection of multiple genomic targets implicated in ALL. The aim of our study was to evaluate the utility of dMLPA in screening of ALL patients for key CNAs. Here, we present (1) the spectrum of chromosomal abnormalities, and CNAs including gene alterations among B-ALL and T-ALL patients, (2) validation of dMLPA data by conventional MLPA and RT-PCR, (3) correlation of CNAs with Minimal Residual Disease (MRD) status and integration of CNAs with risk stratification in ALL. As far as we know, our study demonstrated the utility of dMLPA in the detection of CNAs in ALL for the first time in Indian patients.

A Little About The Authors:

Prof. Dr. Ritu Gupta, Professor & Head Laboratory Oncology Unit, Dr. BRA IRCH, All India Institute of Medical Sciences, New Delhi, India. She is one of the worldwide beta testers for digitalMLPA and has been using this product for the past couple of years. 

Along with her, her colleagues – Dr. Gurvinder Kaur and Dr. Deepshi Thakral have also been pioneers in using digitalMLPA. There are also other members of the Department of Medical Oncology, Dr. BRAIRCH, and Department of Pediatrics from All India Institute of Medical Sciences, New Delhi who have been a part of this project. MRC Holland has also contributed their inputs to it as it is a novel technology and this was one of the first projects on it.